Biotech · Private company · Carlsbad, CA, US
Arisan Therapeutics, Inc.
Track this companyFree. Adds Arisan Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials30 recruiting or active
Pipeline programs5From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline5
- ARN-75039 highPhase 2 · Lassa FeverClinicalTrials.gov · fetched Nov 12, 2026
- ARN-75039 lowPhase 2 · Lassa FeverClinicalTrials.gov · fetched Nov 12, 2026
- Intravenous ribavirinPhase 2 · Lassa FeverClinicalTrials.gov · fetched Nov 12, 2026
- ARN-75039Phase 1 · Healthy VolunteerClinicalTrials.gov · fetched Nov 12, 2026
- ARN-75039 oral capsulesPhase 1 · Healthy Adult ParticipantsClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- ARN-75039 Lassa Fever Treatment in West AfricaPHASE2 · SUSPENDED · started Feb 14, 2026ClinicalTrials.gov NCT07419373 · fetched Nov 12, 2026
- A Comparison of the Pharmacokinetic Properties of ARN-75039 Tablets With Excipients to Neat ARN-75039 in Hydroxypropyl Methylcellulose (HPMC) Capsules in Healthy Adult Participants Under Fed ConditionsPHASE1 · COMPLETED · started Feb 27, 2025ClinicalTrials.gov NCT06911242 · fetched Nov 12, 2026
- A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ARN-75039 in Healthy Adult SubjectsPHASE1 · COMPLETED · started Jan 23, 2023ClinicalTrials.gov NCT05735249 · fetched Nov 12, 2026
NIH awards6
- Initiation of ARN-75039 API and Drug Product NDA Registration Path and Manufacturing of Phase 3 final Drug ProductFiscal year 2026 · $1MNIH RePORTER 5SB1AI112097-10 · fetched Nov 12, 2026
- Development of Therapeutic Candidates for Emerging Infectious DiseasesFiscal year 2026 · $2.9MNIH RePORTER 75N93026C00012-0-9999-1 · fetched Nov 12, 2026
- IND-Enabling Studies for Arenavirus Preclinical CandidateFiscal year 2025 · $915.1KNIH RePORTER 5R01AI160246-05 · fetched Nov 12, 2026
- Initiation of ARN-75039 API and Drug Product NDA Registration Path and Manufacturing of Phase 3 final Drug ProductFiscal year 2025 · $1MNIH RePORTER 5SB1AI112097-09 · fetched Nov 12, 2026
- Initiation of ARN-75039 API and Drug Product NDA Registration Path and Manufacturing of Phase 3 final Drug ProductFiscal year 2024 · $1MNIH RePORTER 2SB1AI112097-08A1 · fetched Nov 12, 2026
- IND-Enabling Studies for Arenavirus Preclinical CandidateFiscal year 2024 · $1.1MNIH RePORTER 5R01AI160246-04 · fetched Nov 12, 2026